Livingston PO - Search Results

1

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Nasi ML, et al. Among authors: livingston po. Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Melanoma Res. 1997. PMID: 9578432 Review.

2

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.

Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. Chapman PB, et al. Among authors: livingston po. Vaccine. 2004 Jul 29;22(21-22):2904-9. doi: 10.1016/j.vaccine.2003.12.028. Vaccine. 2004. PMID: 15246627 Clinical Trial.

3

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. Chapman PB, et al. Among authors: livingston po. Clin Cancer Res. 2004 Jul 15;10(14):4717-23. doi: 10.1158/1078-0432.CCR-04-0345. Clin Cancer Res. 2004. PMID: 15269144 Clinical Trial.

4

Vaccines and other adjuvant therapies for melanoma.

Wolchok JD, Livingston PO, Houghton AN. Wolchok JD, et al. Among authors: livingston po. Hematol Oncol Clin North Am. 1998 Aug;12(4):835-48, vii. doi: 10.1016/s0889-8588(05)70026-5. Hematol Oncol Clin North Am. 1998. PMID: 9759582 Review.

5

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. McCaffery M, et al. Among authors: livingston po. Clin Cancer Res. 1996 Apr;2(4):679-86. Clin Cancer Res. 1996. PMID: 9816218 Clinical Trial.

6

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.

Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Yao TJ, et al. Among authors: livingston po. Clin Cancer Res. 1999 Jan;5(1):77-81. Clin Cancer Res. 1999. PMID: 9918205 Clinical Trial.

7

Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.

Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Ragupathi G, et al. Among authors: livingston po. Int J Cancer. 2000 Mar 1;85(5):659-66. doi: 10.1002/(sici)1097-0215(20000301)85:5<659::aid-ijc11>3.0.co;2-5. Int J Cancer. 2000. PMID: 10699946 Clinical Trial.

8

Clinical results using biochemotherapy as a standard of care in advanced melanoma.

Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Chapman PB, et al. Among authors: livingston po. Melanoma Res. 2002 Aug;12(4):381-7. doi: 10.1097/00008390-200208000-00011. Melanoma Res. 2002. PMID: 12170188

9

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.

Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Hwu WJ, et al. Among authors: livingston po. J Clin Oncol. 2002 Jun 1;20(11):2610-5. doi: 10.1200/JCO.2002.09.034. J Clin Oncol. 2002. PMID: 12039921 Clinical Trial.

10

Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.

Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB. Wolchok JD, et al. Among authors: livingston po. Melanoma Res. 2003 Apr;13(2):189-96. doi: 10.1097/00008390-200304000-00013. Melanoma Res. 2003. PMID: 12690304 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters